Physician profile
Ehab Sargious
NPI 1619968427
$4,072.07
in general payments reported to CMS, 2019-2025
21 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $648 · 2021: $1,274 · 2022: $711 · 2023: $645 · 2024: $333 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,194.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $827.84 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $551.41 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $510.60 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $340.03 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $313.88 | 2019-2023 | Trintellix |
| Lundbeck LLC | $283.63 | 2020-2025 | Rexulti, Abilify Maintena |
| Allergan, INC. | $268.03 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $229.38 | 2020-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $212.10 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Eisai INC. | $132.22 | 2020-2021 | |
| Alkermes, INC. | $81.84 | 2019-2025 | Aristada, Lybalvi |
| Sage Therapeutics, LLC | $60.82 | 2024 | |
| Neurocrine Biosciences, INC. | $60.14 | 2019-2024 | Ingrezza |
| Merck Sharp & Dohme LLC | $37.63 | 2021 | |
| Jazz Pharmaceuticals INC. | $34.17 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $31.30 | 2019 | |
| Axsome Therapeutics, INC. | $28.92 | 2022-2024 | Auvelity |
| Owp Pharmaceuticals, INC. | $20.36 | 2020 | |
| Supernus Pharmaceuticals, INC. | $16.68 | 2024 | Qelbree |
| Almatica Pharma LLC | $16.14 | 2022 | |
| Noven Therapeutics, LLC | $14.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ehab Sargious listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.